Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Condition:   Myeloproliferative Neoplasm
Intervention:   Drug: Fedratinib Pill
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 20, 2021Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments